Boji Medical controlling shareholder completes share reduction plan

Guangzhou Boji Medical & Biotechnological (Boji Medical) announced its controlling shareholder, Mr. Wang Tingchun, along with Ms. Zhao Limi and Fermithirteen Private Fund, have completed their share reduction plan. From September 12, 2025, to December 10, 2025, a total of 11,486,500 shares were divested through block trades and centralized bidding, representing 2.98% of the company's total share capital (3.00% after excluding shares in the dedicated repurchase account).

Following the completion, Mr. Wang Tingchun, Ms. Zhao Limi, and Fermithirteen Private Fund collectively hold 131,944,190 shares, equating to 34.21% of the total share capital (34.44% excluding repurchased shares). This marks a decrease from their previous collective holding of 143,430,690 shares, or 37.20%. The average selling prices for Mr. Wang's block trades were CNY 8.52 per share, while Fermithirteen's centralized bidding sales averaged CNY 10.18 per share.

The company confirmed this equity change will not alter its control or have a significant impact on its ongoing operations. The share reduction was conducted in accordance with regulatory requirements and aligns with previously disclosed intentions and commitments.